Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0TAOLW)
| ADC Name |
LY203725
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
LY203725
Click to Show/Hide
|
|||||
| Organization |
Eli Lilly (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
4-6
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
KS1/4
|
Antibody Info | Antigen Name |
Undisclosed
|
||
| Payload Name |
4-desacetylvinblastine (DAVLB)
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| Combination Type |
KS1/4-DAVLB
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Ovarian cancer |
1 Trials
|